Most Recent
Vanguard hit with record $12.9M penalty in ASIC greenwashing case
Vanguard Investments has been ordered to pay a penalty of almost $13 million for misleading the public about its $1 billion “ethically conscious” hedge fund.
Suit alleges barrister used $1.3M of his company’s funds for chambers fees
Shareholders in lending platform Marketlend can bring a derivative suit against its directors for allegedly misusing company funds, including spending $1.3 million on barrister chambers fees. 
High Court refuses special leave in Syria repatriation fight
Human rights group Save the Children has lost its fight to release Australians held in a Syrian refugee camp after the High Court refused its special leave bid. 
Ex-Linchpin director loses appeal of $150,000 penalty
The director of collapsed investment firm Linchpin Capital has lost his challenge to a $150,000 penalty, with an appeals court dismissing his arguments as “carping criticism”.
Advanta Seeds can’t force licensee Nuseed to fix seed labels
The developer of a Canola seed hybrid tolerant to herbicide has lost a bid for seed grower Nuseed to relabel its products, which are already stocked in 361 retail locations.
‘Horse has bolted’: Judge declasses COVID-19 insurance class actions
Four proceedings over COVID-19 business interruption losses will be stripped of class action status, with a judge saying most of the common issues were already determined in test cases.
Super Retail hit with second Fair Work case in Federal Court
Super Retail faces a second Federal Court case by a former senior female executive, after conciliation proceedings in the Fair Work Commission failed to resolve the complaint.
CBA class actions win halt to costs battle pending appeal
Applicants in two dismissed class actions against the Commonwealth Bank have secured an order staying an assessment of costs in the failed cases until the outcome of an appeal.
Lundbeck wins appeal in decade-long IP battle with Sandoz over Lexapro
Pharmaceuticals giant Lundbeck has succeeded in overturning IP Australia’s decision granting Novartis unit Sandoz a licence to sell a generic version of top-selling antidepressant Lexapro.
Insurers on hook for Opal Tower class action costs after failed appeal
Two insurers have come up short in their appeal of a ruling that put them on the hook for the costs of Opal Tower consultant engineer WSP in a class action by residents.